La problemática de ñas especialidades farmaceuticas complejasuna aproximación desde la farmacia comunitaria
- GARCIA DE BICUÑA, BORJA
- Joaquín Giráldez Deiró Director
- Azucena Aldaz Pastor Codirectora
Universidad de defensa: Universidad de Navarra
Fecha de defensa: 15 de diciembre de 2005
- Eduardo Mariño Hernandez Presidente/a
- Guadalupe Beitia Berrotarán Secretaria
- María Teresa Pagés Giménez Vocal
- María Jesús Renedo Omaechevarría Vocal
- José Javier Velasco del Castillo Vocal
Tipo: Tesis
Resumen
La problemática de las especialidades farmacéuticas complejas: una aproximación desde la farmacia comunitaria Resumen: An approach from the community pharmacy to the problems created by complex pharmaceutical products Complex Pharmaceutical Products (cpps) have been defined for the first time as those which créate some difficulty when they are administered, either because the patient requires some sort of preparation previous to their intake or/and because a technique related to their administration must be 1earnt. a method to identify the 1240 CPPs included in the Year 2003 catalogue issued by the General Board of Official Pharmaceutical Colleges has been described and the largest groups correspond to those ophthalmically (211), rectally (202) and orally (164) administered. workshops and courses on CPPs have proved to be very useful. The correct answers given by pharmacists who had attended them increased by 29,02%, whereas incorrect answers decreased by 22,5%. Pharmacists attending the workshops were highly motivated. 90,4% considered CPPs an interesting issue and 98,4% stated pharmacists were to instruct patients in their handling. There is illustrated material on CPPs which provides patients with the required explanations. 47,7% of patients enquired had no information on the prescribed CPP and only 0,9% refused to accept the pharmacist's illustrated explanation. 71,1% of patients considered the pharmacist's explanation useful and 93,0% were satisfied with the demonstration. In general, the pharmaceutical industry is not aware of the problems these produces create. Therefore, it must be concluded that the government, the pharmaceutical industry and the health professionals must agree on the contents, the quality and the aim of the enclosed directions for use